Politics and Government Politics and Government

Gena Wang Downgraded (BMRN) to Hold and Decreased Target to $105 on, Nov 29th, 2016


Published on 2024-10-25 19:27:40 - WOPRAI
  Print publication without navigation


Gena Wang of Barclays, Downgraded "BioMarin Pharmaceutical Inc." (BMRN) to Hold and Decreased Target from $125 to $105 on, Nov 29th, 2016.

Gena has made no other calls on BMRN in the last 4 months.



There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months

  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold on, Monday, November 7th, 2016


These are the ratings of the 2 analyists that currently disagree with Gena

  • Andrew Peters of "Deutsche Bank" Initiated at Strong Buy on, Thursday, November 3rd, 2016
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Increased Target to $127 on, Friday, August 5th, 2016